Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

8.07
-0.1500-1.82%
Post-market: 7.97-0.1000-1.24%16:55 EST
Volume:1.05M
Turnover:8.49M
Market Cap:1.11B
PE:-2.11
High:8.31
Open:8.06
Low:7.99
Close:8.22
Loading ...

Vir Biotechnology reports ‘positive’ end-of-treatment data from MARCH study

TIPRANKS
·
16 Nov 2024

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Business Wire
·
16 Nov 2024

Analysts Conflicted on These Healthcare Names: Vir Biotechnology (VIR) and Moderna (MRNA)

TIPRANKS
·
06 Nov 2024

Vir Biotechnology Is Maintained at Overweight by Barclays

Dow Jones
·
04 Nov 2024

Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Nov 2024

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results

Simply Wall St.
·
04 Nov 2024

Vir Biotechnology price target lowered to $26 from $28 at Barclays

TIPRANKS
·
04 Nov 2024

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vir Biotechnology (VIR), Cardinal Health (CAH) and Waters (WAT)

TIPRANKS
·
04 Nov 2024

Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
02 Nov 2024

Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...

GuruFocus.com
·
02 Nov 2024

Vir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates

Dow Jones
·
02 Nov 2024

Bank of America Securities Sticks to Their Hold Rating for Vir Biotechnology (VIR)

TIPRANKS
·
01 Nov 2024

Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago

Simply Wall St.
·
01 Nov 2024

Stock Track | Vir Biotech Soars 5.74% on Analyst Optimism Despite Mixed Earnings

Stock Track
·
01 Nov 2024

Vir Biotechnology Price Target Maintained With a $19.00/Share by Needham

Dow Jones
·
01 Nov 2024

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Intra-Cellular Therapies (ITCI) and Neurocrine (NBIX)

TIPRANKS
·
01 Nov 2024